Toshinari Yamashita

15PUBLICATIONS
64CO-AUTHORS
Environmental epidemiologyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsModels of care and place of birthPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jul 08, 2026
Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD.

|Jun 10, 2026
Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer.

|Mar 28, 2026
Association Between Single-Nucleotide Polymorphism and Trastuzumab Deruxtecan-Induced Interstitial Lung Disease in Breast Cancer Using the Japonica Array NEO.

Saori Fujiwara, Nao Saito, Mio Yasukawa

|May 11, 2025
Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC.

Naoto T Ueno, Francesco Cottone, Kyle Dunton

|Apr 17, 2025
First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer.

Timothy A Yap, Jonathan W Goldman, Shaveta Vinayak

|Jan 09, 2025
Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.

Toshinari Yamashita, Shigehira Saji, Toshimi Takano

Pageof 3

Frequent Collaborators

5 joint publications

Norikazu Masuda

3 joint publications

Shigehira Saji

3 joint publications

Yoichi Naito

3 joint publications

Erika Hamilton